| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30007092 | HIV | ENSG00000131747.15 | protein_coding | TOP2A | Yes | No | 7153 | P11388 |
| TVIS30001285 | HIV | ENSG00000131747.15 | protein_coding | TOP2A | Yes | No | 7153 | P11388 |
| TVIS30012289 | HIV | ENSG00000131747.15 | protein_coding | TOP2A | Yes | No | 7153 | P11388 |
| TVIS30007093 | HIV | ENSG00000131747.15 | protein_coding | TOP2A | Yes | No | 7153 | P11388 |
| TVIS30004635 | HIV | ENSG00000131747.15 | protein_coding | TOP2A | Yes | No | 7153 | P11388 |
| TVIS30007094 | HIV | ENSG00000131747.15 | protein_coding | TOP2A | Yes | No | 7153 | P11388 |
| TVIS30015466 | HIV | ENSG00000131747.15 | protein_coding | TOP2A | Yes | No | 7153 | P11388 |
| TVIS30013971 | HIV | ENSG00000131747.15 | protein_coding | TOP2A | Yes | No | 7153 | P11388 |
| TVIS30004636 | HIV | ENSG00000131747.15 | protein_coding | TOP2A | Yes | No | 7153 | P11388 |
| TVIS30007095 | HIV | ENSG00000131747.15 | protein_coding | TOP2A | Yes | No | 7153 | P11388 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | TOP2A |
|---|---|
| DrugBank ID | DB00997 |
| Drug Name | Doxorubicin |
| Target ID | BE0000742 |
| UniProt ID | P11388 |
| Regulation Type | inhibitor |
| PubMed IDs | 11752352; 17010609; 17351394; 17016621; 17578914; 17089011; 30391699 |
| Citations | Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Rody A, Karn T, Gatje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhaberle E, Holtrich U, von Minckwitz G, Kaufmann M: Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast. 2007 Feb;16(1):86-93. Epub 2006 Sep 28.@@Koehn H, Magan N, Isaacs RJ, Stowell KM: Differential regulation of DNA repair protein Rad51 in human tumour cell lines exposed to doxorubicin. Anticancer Drugs. 2007 Apr;18(4):419-25.@@Hayashi S, Hatashita M, Matsumoto H, Shioura H, Kitai R, Kano E: Enhancement of radiosensitivity by topoisomerase II inhibitor, amrubicin and amrubicinol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction. Int J Mol Med. 2006 Nov;18(5):909-15.@@Azarova AM, Lyu YL, Lin CP, Tsai YC, Lau JY, Wang JC, Liu LF: Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):11014-9. Epub 2007 Jun 19.@@Menendez JA, Vellon L, Lupu R: DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes. Int J Mol Med. 2006 Dec;18(6):1081-7.@@Khalil OM, Gedawy EM, El-Malah AA, Adly ME: Novel nalidixic acid derivatives targeting topoisomerase II enzyme; Design, synthesis, anticancer activity and effect on cell cycle profile. Bioorg Chem. 2019 Mar;83:262-276. doi: 10.1016/j.bioorg.2018.10.058. Epub 2018 Oct 30. |
| Groups | Approved; Investigational |
| Direct Classification | Anthracyclines |
| SMILES | COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O |
| Pathways | Doxorubicin Metabolism Pathway |
| PharmGKB | PA449412 |
| ChEMBL | CHEMBL53463 |
